Clinical analysis of recombinant human interleukin-11 in treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumors

The objective of this study was to evaluate the efficacy and safety of recombinant human interleukin-11 in the treatment of thrombocytopenia caused by chemotherapy in patients with malignant tumors.The clinical data of 73 patients were analyzed retrospectively.The patients were given recombinant human interleukin-11(rhIL-11) when their platelet count was 75×109 L-1.The effective rate in the totle patients was 93.2% with the treatment duration of 4-23(7.4±4.2) days.The effective rate in the 50 patients whose platelet count was 50×109 L-1 was 92.0%.The patients who had grade Ⅱ thrombocytopenia were given rhIL-11 for 4-9(5.0±1.4) days,and their platelet count was(62.8±6.1)×109 L-1 when rhIL-11 was given.The patients who had grade Ⅲ/Ⅳ thrombocytopenia were given rhIL-11 for 4-23(8.5±4.6) days,and their platelet count was(39.8±18.6)×109L-1.These differences were significant(P0.05).The count of platelets when rhIL-11 was administrated was negatively related with the efficacy and the treatment duration(P0.05).The side effects included edema,heart-throb,chest discomfort,muscle and joint pain,fatigue and slight fever,etc.In conclusion,rhIL-11 is effective and safe in the treatment of thrombocytopenia caused by chemotherapy in patients with malignant tumors.The efficacy will be better if it is given earlier.